Novo Holdings
Novo Holdings, established in 1999, is the holding company of the Novo Group, primarily managing the investment assets of the Novo Nordisk Foundation. Based in Copenhagen, with additional offices in San Francisco and Boston, Novo Holdings focuses on two main investment categories: Life Science Investments, which encompasses funding life science companies at various stages of development, and Financial Investments, which entails managing a diversified portfolio of equity and fixed income securities. As a prominent life science investor, Novo Holdings aims to create long-term value while ensuring that the Foundation can distribute returns for scientific, social, and humanitarian purposes to enhance public health and welfare. The company has also developed initiatives such as Novo Seeds, which supports early-stage applied research in life sciences, and invests in later-stage life science companies through growth equity. Novo Holdings maintains a strategic influence over affiliated companies, aligning their operations with the values and objectives of the Novo Group.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Mission Bio, Inc. specializes in tools for studying cellular heterogeneity in human health and life science research. The company utilizes microfluidic droplet technology to provide solutions for molecular analysis at the single-cell level. Its flagship product, the Tapestri Platform, is the first single-cell multi-omics platform, allowing for the simultaneous detection of genotype and phenotype from the same cell, which enhances the understanding of disease progression and treatment responses. Additionally, Mission Bio offers Tapestri Designer, a cloud-based tool for creating targeted single-cell DNA custom panels, applicable in various fields including oncology, blood cancers, solid tumors, and genome editing validation. Founded in 2011 and based in South San Francisco, California, the company was previously known as Torrent Bio, Inc. before rebranding in 2013.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
Morphic Therapeutic is a biotechnology company focused on developing oral small-molecule integrin therapeutics for various medical conditions, including autoimmune diseases, cardiovascular issues, metabolic disorders, fibrosis, and cancer. Its lead candidates in clinical development include MORF-720, an avß6 specific integrin inhibitor targeting idiopathic pulmonary fibrosis and primary sclerosing cholangitis, and MORF-057, an a4ß7 specific integrin inhibitor for inflammatory bowel disease. The company is also exploring additional integrin inhibitors for similar applications. Founded in 2015, Morphic Therapeutic has established collaborations with various organizations, including Engitix Ltd, Schrödinger, LLC, AbbVie Biotechnology Ltd, and Janssen Pharmaceuticals, to advance its research and development efforts. The company is headquartered in Waltham, Massachusetts, and leverages scientific discoveries made by its founder Tim Springer to innovate in the field of integrin therapies.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Milestone Pharmaceuticals Inc., a biopharmaceutical company, develops and commercializes etripamil for the treatment of cardiovascular indications. It is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for the treatment of atrial fibrillation, angina, and other cardiovascular indications. The company was founded in 2003 and is headquartered in Montréal, Canada.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
NMD Pharma is a small molecule drug discovery company that develops novel treatments of neuromuscular disorders.
Research by the founders working on the neuromuscular junction identified an approach that has not previously been exploited but shows great promise.
Importantly, the approach improves neuromuscular transmission in a way that is potentially applicable to a range of clinical indications and orphan human diseases that have profound unmet medical need.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
Tarsa Therapeutics, Inc. develops therapies for the treatment and prevention of osteoporosis and related bone diseases in women. It develops TBRIA, an oral formulation of salmon calcitonin used in the treatment of postmenopausal osteoporosis. The company offers clinical programs, such as osteoporosis treatment and osteoporosis prevention programs. Tarsa Therapeutics, Inc. was formerly known as Boneco, Inc. The company was founded in 2009 and is based in Philadelphia, Pennsylvania.
7TM Pharma
Series D in 2007
7TM Pharma is a biotech company that discovers and develops drugs with a primary therapeutic focus on diabetes, gastrointestinal, metabolic, asthma, and vascular diseases. The company offers seven transmembrane-spanning receptors, including TM38837, a small molecule CB1 receptor antagonist; TM30339, a NPY Y4 selective agonist that is used within gastrointestinal disorders, and short bowel syndrome; and CRTH2 antagonist, an oral drug for inflammatory or respiratory diseases. 7TM Pharma was founded in 2000 and is based in Lyngby, Hovedstaden.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.
BioMimetic Therapeutics is a biotechnology company that develops products to help stimulate the body natural tissue regenerative process. The company's products and product candidates include Augment Injectable and Augment Rotator Cuff for several orthopedic and sports medicine indications comprising the treatment of foot and ankle fusions, the stimulation of wrist fracture healing, and the surgical treatment of rotator cuff tears, as well as Augment Tendinopathy Injection for injuries cause of tendon overuse. BioMimetic Therapeutics was founded on 1999 and is headquartered in Franklin, Tennessee.